Exabis Library
Welcome to the e-CCO Library!
P383: Ustekinumab as an opportunity for refractory Ulcerative Colitis patients.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P384 Lower infliximab trough levels are associated with higher bowel wall thickness in Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P384: A higher red blood cell methotrexate polyglutamate 3 concentration is associated with methotrexate drug-survival in patients with Crohn's Disease: first results of a prospective cohort
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P384: Gari-leo prospective study on anti-TNF therapy in ulcerative colitis relapse patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P384: High incidence of hyperglycaemia in steroid treated hospitalised inflammatory bowel disease (IBD) patients and its risk factors identified by machine learning methods
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P384: Long-term outcome and endoscopic healing rates following long modified side-to-side strictureplasties
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P384: Postoperative Endoscopic Recurrence In Patients With Crohn’s Disease After “Curative” Ileocecal Resection on Prophylaxis Treatment With Either Anti-TNFs, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P384: The usefulness of salazosulfapyridine for
patients with ulcerative colitis refractory to mesalazine
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P384: Therapeutic drug monitoring: performance of the first lateral flow-based Point of Care test for the quantification of infliximab in a finger prick
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P385 A mucosal marker predicting tofacitinib induced an endoscopic response in ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P385: Assessment of long-term outcomes of patients with ulcerative colitis and mucosal healing under different therapies: Is all mucosal healing the same?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P385: Colectomy-free survival and factors associated with it in children with ulcerative colitis managed in a tertiary IBD centre in the UK
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P385: Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P385: Results of a teleconsultation campaign for Inflammatory Bowel Disease (IBD) patients to check their treatment adherence and assess their level of anxiety during the first COVID-19 lockdown
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P385: Risk-benefit assessment of IBD drugs: a physicians and patients survey
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P385: Tailoring induction treatment for children with Crohn’s disease.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P385: TREM1, the first anti-TNF specific biomarker guiding therapeutic decision
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P386 Long-term evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (IBD): A multicentre study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P386: A target 6-thioguanine nucleotide ≥125 is associated with a higher rate and longer durability of response in infliximab–thiopurine combination therapy: a retrospective study in Crohn's disease patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P386: Anti-TNF alpha as induction and maintenance therapy in ulcerative colitis patients in the BioColitis Registry in Germany
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM